Alkermes Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Decisions with the Full Value Chain Report
This Alkermes Value Chain Analysis gives you a clear, structured view of how Alkermes creates value across support activities and primary activities. This page already shows a real preview of the actual analysis, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
In FY2025, Alkermes used a centralized governance model to steer capital across 3 marketed medicines, CNS R&D, and partnered programs. That discipline matters when R&D and commercialization both need funding, because it keeps late-stage bets from crowding out core cash generation. Tight oversight also helps Alkermes protect decision speed and capital efficiency.
Human Resource Management
Alkermes' human resource management is built around scientists, formulation experts, regulatory staff, manufacturing specialists, and specialty commercial teams, because CNS trials and quality systems need deep know-how. In fiscal 2025, Alkermes reported about $1.5 billion in total revenue, which shows how much this talent base supports the business. Those teams also help move provider-facing launches with tighter execution and faster issue resolution.
Technology Development
Alkermes' proprietary formulation and drug-delivery platform is its core edge, enabling long-acting injectables like ARISTADA and VIVITROL and the oral fixed-dose combo LYBALVI. As of FY2025, this technology supports a portfolio built around 3 marketed CNS medicines and multiple pipeline programs in schizophrenia, bipolar I disorder, and other CNS uses. The result is lower dosing frequency and better treatment persistence, which strengthens pricing power and lifecycle value.
Procurement
Alkermes' procurement focuses on APIs, excipients, packaging, and specialized development and manufacturing services from qualified suppliers. In a regulated drug supply chain, supplier quality and dual sourcing help protect batch success, continuity, and compliance.
This matters because even one failed lot can delay launch or disrupt patient supply, so procurement is tied directly to operating risk and manufacturing efficiency.
Alkermes' FY2025 backbone powered CNS execution and growth
In FY2025, Alkermes' support activities were built to protect its CNS portfolio: centralized governance steered capital, expert teams ran R&D and commercialization, and its delivery platform supported 3 marketed medicines. With about $1.5 billion in revenue, this backbone helped fund execution while keeping quality and launch risk in check.
| Support area | FY2025 signal |
|---|---|
| Governance | Capital discipline |
| Human resources | Specialist teams |
| Technology | Long-acting delivery |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Alkermes receives and tests APIs, excipients, and packaging materials under strict supplier-qualification and incoming-release controls, which is critical for regulated CNS medicines. In fiscal 2025, Alkermes reported $1.6 billion in revenue, and that scale depends on clean inputs and low lot-to-lot variation. Tight inbound checks help protect batch quality, reduce scrap, and keep cGMP production on track.
Operations
Alkermes manufactures, tests, and batch-releases its medicines through a tightly controlled pharmaceutical process, turning formulation science into sellable inventory. In fiscal 2025, this operations base supported 3 core marketed products: VIVITROL, ARISTADA, and LYBALVI. The process matters because lot release, quality control, and stable supply directly protect revenue from these commercial brands.
Outbound Logistics
Alkermes routes finished product through wholesalers, specialty pharmacies, and partner-led channels, so outbound control affects fill rates and patient access. In its 2025 reporting, the mix still had to support high-touch launches like LYBALVI and long-acting products such as ARISTADA and VIVITROL, where inventory visibility can make or break refill timing. Reliable shipping, traceability, and channel coordination also help protect revenue from returns, chargebacks, and stockouts.
Marketing and Sales
In FY2025, Alkermes focused Marketing and Sales on a small branded portfolio, using disease education, access support, and promotion to reach psychiatrists, addiction specialists, neurologists, and payers. This matters because formulary access and channel placement can decide whether a script is written, so the team aims to convert awareness into prescriptions for products like VIVITROL, LYBALVI, and ARISTADA. For a smaller portfolio, each payer win has outsized revenue impact.
Service
Alkermes uses Service to support patients and prescribers with reimbursement help, injection education, safety materials, and adherence resources. For long-acting CNS therapies, this matters because every on-time dose helps keep patients on treatment, and persistence drives repeat sales.
In 2025, this support stayed tied to commercial execution: smoother access, better training, and fewer drop-offs can protect revenue after launch.
Alkermes Turns CNS Manufacturing Into $1.6B in FY2025 Revenue
Alkermes' primary activities in FY2025 turned regulated inputs into branded CNS medicines, with $1.6 billion in revenue driven by VIVITROL, ARISTADA, and LYBALVI. Strong operations and quality control kept batch release, supply, and traceability tight. Outbound logistics and sales support then helped convert access and adherence into prescriptions.
| FY2025 | Revenue | Core products |
|---|---|---|
| Alkermes | $1.6B | VIVITROL, ARISTADA, LYBALVI |
Preview the Actual Deliverable
Alkermes Reference Sources
This preview of the Alkermes Value Chain Analysis is the exact same document you'll receive after purchase – no sample, no substitution. It reflects the full report's professional structure and insights. Once you complete checkout, the complete version is unlocked for immediate use.
Frequently Asked Questions
Alkermes' value chain emphasizes CNS-focused R&D, proprietary drug-delivery technology, regulated manufacturing, and specialty commercialization. The company relies on 3 marketed medicines and a pipeline built for psychiatric and neurological disorders, so value is created upstream in science and operations, then captured downstream through access, distribution, and patient persistence.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.